FDMT Q1 2022 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-39.1% YoY

Gross Profit

-$18M-1489.9% margin

Operating Income

-$26M-2165.1% margin

Net Income

-$26M-2160.6% margin

EPS (Diluted)

$-0.81

QoQ Revenue Growth

+1225.0%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$30M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$325M

Total Liabilities

$29M

Stockholders' Equity

$296M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-39.1%
Gross Profit	-$18M	-$11M	-68.7%
Operating Income	-$26M	-$16M	-61.8%
Net Income	-$26M	-$16M	-60.5%

Geographic Segments

NETHERLANDS

$1M98%

UNITED STATES

$28,0002%